Lindus Therapeutics is a next-generation drug development company that advances in-licensed medicines by combining asset selection expertise with an integrated clinical trial platform. Working with biotech and pharmaceutical partners, Lindus identifies promising assets and develops them through clinical trials, with the aim of reaching key milestones faster and more efficiently. The company focuses on Phase I–III-ready treatments for non-ultrarare chronic diseases aligned with its therapeutic expertise.

Its services span asset identification, clinical development, trial design, patient recruitment, clinical operations, data management, medical oversight, and trial close-out and analysis. Lindus uses proprietary data and AI systems to support asset selection and automate trial processes, while its patient enrollment infrastructure combines electronic health record searches, digital pre-screening, and patient concierge support. Trials are delivered across the United States, the United Kingdom, and Europe, with partnerships in the Asia-Pacific region.

Lindus reports experience across more than 45 Phase I–IV trials and plans to develop assets internally before considering partnerships, acquisitions, later-stage development, or commercialization